medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2016, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (1)

Immunosuppressive triple-therapy using Tymogam® in idiopathic aplastic anemia

Fernández DND, Blanco CA

Language: Spanish
References: 34
Page: 86-98
PDF size: 145.82 Kb.


ABSTRACT

Introduction: immunosuppressive treatment with antithymocyte or antilymphocyte globulin and cyclosporin A is considered the standard treatment for patients with very severe or severe idiopathic aplastic anemia who do not have the possibility of progenitor hematopoietic transplantation.
Objective: to evaluate the responses to immunosuppressive treatment using Thymogam® in adult patients with idiopathic aplastic anemia.
Material and methods: a descriptive study was performed in 26 patients older than 18 years with diagnosis of idiopathic aplastic anemia, attended at the Institute of Hematology and Immunology from January 2000 to April 2012, who received antithymocyte globulin (Thymogam®) as part of immunosuppressive treatment.
Results: patients were classified as very severe (14) and severe ( 12). The median age was 36 years old (range 18-74 years). In the first six months after the start of treatment, 73 % of patients obtained some kind of response and 15 of them (57,6 %) had a complete response, which was more frequent in the group of patients with less of 25 years of age. The percentage of relapse was 26,3 %. The more frequent adverse reactions were fever, arterial hypertension, tremors and sweatiness. The main adverse reactions were severe bleeding and infections. One patient developed acute myeloid leukemia. Overall survival at 5 years was 73 %.
Conclusion: Thymogam® is one therapeutic option in the immunosuppressive treatment in patients with very severe or severe idiopathic aplastic anemia.


REFERENCES

  1. Rovó A, Tichelli A, and Dufour C. Diagnosis of acquired aplastic anemia. Bone Marrow Trasplantation. 2013;48(2):162-7. doi:10.1038/btm.2012.230

  2. Miamo M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int J Hematol. 2015;101:527-35. DOI.10.1007/s2185-015-1787-z

  3. Xie X, Shi W, Zhou X, Shao Y, Qiac X. Comparison of rabbit antithymocyte globulin and Jurkat cell-reactive anti-t lymphocyte globulin as a first –line treatment for children with aplastic anemia. Exp Hematol. 2014 Jun;42(6):43138. doi: 10.1016/j.exphem.2014.02.003.

  4. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, UDϋhrsen U, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocite globulin (GAT), cyclosporine with or without G-CSF. Blood. 2011 Apr;117(17):4434-41. doi: 10.1182/blood-2010-08-304071.

  5. Lichtman MA, Kaushansky K, Kips TH, Prchal JT, Levi MM. Williams Manual Hematología. 8va Ed. Bogotá: Mc Graw-Hill Interamericana. 2014.

  6. Challen GA, Boles NC, Chambers SM, Goodell MA. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta 1. Cell Stem Cell. 2010 Mar;6(3):265-78. doi: 10.1016/j.stem.2010.02.002.

  7. Young NS. Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2013;2013:76-81. doi: 10.1182/asheducation-2013.1.76.

  8. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Gutiérrez-Aguirre CH, Cantú.Rodríguez OG, Sobrevilla-Calvo P, et al. Allografting in patients with severe refractory aplastic anemia using peripheral blood stem cell and a fludarabine based conditioning regimen: the Mexican experience. Am J Hematol. 2006;81:157-61.

  9. Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Trasplantation. 2013;48:183-85. doi:10.1038/btm.2012.231

  10. Dufour C, Svahn J, Bacigalupo A, Severe Aplastic Anemia–Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Trasplantation. 2013;48(2):174-7. doi:10.1038/btm.2012.222

  11. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmaier H, German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporine A: 11 year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003 Feb;101(4):1236-42.

  12. Schrezenmeier H, Körper S, Höchsmann B. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients. Expert Rev Hematol. 2015 Feb;8(1):89- 99. doi: 10.1586/17474086.2015.978759.

  13. Shin SH, Lee SE, Lee JW. Recent advances in treatment of aplastic anemia. Korean J Intern Med. 2014;29(6):713-26.

  14. Camitta PM, Thomas ED, Nathan DG. Severe aplastic anemia: a prospective study on the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63-70.

  15. Risitano AM, Schrezenmeier H. Alternative immunosuppression in patient failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).Bone Marrow Trasplantation. 2013;48:186-90. doi:10.1038/btm.2012.245.

  16. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Colin O, et al. Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia. N Engl J Med. 2011;365:430-8.

  17. Teramura M. Bone marrow failure syndrome (idiopathic hematopoietic disorders): progress in diagnosis and treatment. Topic: III. Diagnosis and treatments; aplastic anemia. Nihon Naika Gakkai Zasshi. 2012;101(7):1928-36.

  18. Gafter-Gvili A, Ram R, Raanani P, Shpilberg O. Management of aplastic anemia: the role of systematic reviews and meta-analysis. Acta Haematol. 2011;125(1-2):47- 54. doi: 10.1159/000318893.

  19. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012 Aug;120(6):1185-96. doi: 10.1182/blood-2011-12-274019.

  20. Pawelec K, Salamonowicz M, Panasiuk A, Demkow U, Kowalczyk J, Balwierz W. First-line immunosppressive treatment in children with aplastic anemia: rabbit antithymocyte globulin. Adv Exp Med Biol. 2015; 836 Jan 1:55-62.

  21. Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A et al. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Ann Hematol. 2015 Jun;94(6):947-54. doi: 10.1007/s00277-015-2305-3.

  22. Wei J, Huang Z, Guo J, Zhang Y, Wang C, Zhu X, et al. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis. Ann Hematol. 2015 Jun;94(6):955–62 doi 10.1007/s00277-015-2308-0.

  23. Agarwal MB, Jijina F, Shah S, Malhotra P, Damodar R, Ross C. safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia. Indian J Hematol Blood Transfus. 2015.31(2):174-9. doi: 10.1007/sl2288-01-0423-z.

  24. Aljurf M and Maury S. Management of adult patients older than 40 years refractory to at least one immunosuppressive course: HLA –identical sibling HSCT using fludarabine- based conditioning. Bone Marrow Trasplantation. 2013;48:196-7. doi:10.1038/btm.2012.251.

  25. Tichelli A and Marsh JCW. Treatment of aplastic anemia in elderly patients aged > 60 years. Bone Marrow Trasplantation. 2013;48:180-82. doi:10.1038/btm.2012.224.

  26. Marsh J, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, Keidan AL, et al. Guidelines for the diagnosis and management of aplastic anemia. Br J Hematol. 2009;147:43-70.

  27. Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof ET, Bekassy A, et al. Outcomes of patients with acquired aplastic anemia given first line bone marrow trasplantation or immunosuppressive treatment in the last decade. Haematologica. 2007;92:11-8.

  28. Ngwube A, Hayashi RJ, Murray LLoechelt B, Dalal J, Jaroscak J, et al. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015 Mar 8. doi: 10.1002/pbc.25458.

  29. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006:108:2509-19.

  30. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults Blood 2007:110:1756-61.

  31. Chul-Jeong D, Gyun-Chun N, Cho B, Zou Y, Ruan M, Takahashi Y, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014 Apr;99(4):664-71. doi: 10.3324/haematol.2013.089268.

  32. Chandra J, Naithani R, Ravi R, Sing V, Narayan S, Sharma S. Antuthymocyte globulin and Cyclosporin in children with acquired aplastic anemia. Indian J Pediatr. 2008 Mar;75(3):229-33.

  33. Forester CM, Sartain SE, Guo D, Harris MH, Weinberg OK, Fleming MD, et al. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol. 2015;90(4):320-26. DOI:10.1002/ajh.23937

  34. Pawelec K, Salamonowicz M, Panasiuk A, Demkow U, Kowalczyk J, Balwierz W, et al. First-Line immunosuppresive treatment in children with aplastic anemia: Rabbit antithymocyte globulin. Adv Exp Med Biol. 2015;836:55-62. doi: 10.1007/5584_2014_38.




2020     |     www.medigraphic.com